KIF5B: A Potential Drug Target and Biomarker (G3799)

Target Name: KIF5B

NCBI ID: G3799

KIF5B

KIF5B: A Potential Drug Target and Biomarker

Kinesin family member 5B (KIF5B) is a protein that plays a critical role in the proper functioning of mitochondria, which are responsible for generating energy in the cell. Mitochondria are found in nearly every cell of the body and are known for their ability to produce reactive oxygen species (ROS) that can damage cellular components and contribute to a range of diseases, including cancer. Therefore, targeting KIF5B and modulating its activity has the potential to be a valuable therapeutic approach for the prevention and treatment of a variety of diseases.

KIF5B is a 21-kDa protein that is expressed in most tissues of the body. It is a key component of the mitochondrial inner membrane, which is a thin layer of protein and lipids that surrounds the mitochondria and facilitates their function. is involved in the formation of the mitochondrial outer membrane, which is a double layer of protein and lipids that encapsulates the mitochondria and regulates their access to the cytosol, the space outside the mitochondria where cellular processes occur.

In addition to its role in regulating the mitochondria, KIF5B is also involved in the regulation of cellular processes that are critical for cell survival. It has been shown to be involved in the regulation of cell growth, apoptosis (programmed cell death), and autophagy (the process by which cells break down and recycle their own damaged or unnecessary components).

Given its involvement in so many cellular processes, KIF5B has naturally emerged as a potential drug target. Several studies have suggested that KIF5B may be a drug target for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In cancer, KIF5B has been shown to be involved in the regulation of cell growth, angiogenesis (the process by which new blood vessels form in tumors), and the development of drug resistance. Therefore, targeting KIF5B with drugs that can inhibit its activity may be an effective way to treat cancer.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, KIF5B has been shown to be involved in the regulation of the mitochondria and the production of ROS. Therefore, targeting KIF5B with drugs that can modulate its activity may be an effective way to treat these diseases.

In cardiovascular diseases, KIF5B has been shown to be involved in the regulation of cell growth, apoptosis, and the production of ROS. Therefore, targeting KIF5B with drugs that can inhibit its activity may be an effective way to treat cardiovascular diseases, such as heart failure, hypertension, and stroke.

In addition to its potential therapeutic applications, KIF5B is also an attractive biomarker for a variety of diseases. Its expression has been shown to be involved in the progression of several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Therefore, measuring the expression of KIF5B may be a useful diagnostic tool for these diseases.

Overall, KIF5B is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in cellular processes and its potential as a therapeutic approach.

Protein Name: Kinesin Family Member 5B

Functions: Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner (By similarity). Regulates centrosome and nuclear positioning during mitotic entry. During the G2 phase of the cell cycle in a BICD2-dependent manner, antagonizes dynein function and drives the separation of nuclei and centrosomes (PubMed:20386726). Required for anterograde axonal transportation of MAPK8IP3/JIP3 which is essential for MAPK8IP3/JIP3 function in axon elongation (By similarity). Through binding with PLEKHM2 and ARL8B, directs lysosome movement toward microtubule plus ends (Probable). Involved in NK cell-mediated cytotoxicity. Drives the polarization of cytolytic granules and microtubule-organizing centers (MTOCs) toward the immune synapse between effector NK lymphocytes and target cells (PubMed:24088571)

The "KIF5B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF5B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets